Allopregnanolone and mood disorders

@article{Bckstrm2014AllopregnanoloneAM,
  title={Allopregnanolone and mood disorders},
  author={Torbj{\"o}rn B{\"a}ckstr{\"o}m and Marie Bixo and Maja Johansson and Sigrid Nyberg and Lindsey Ossewaarde and Gianna Ragagnin and Ivanka Savic and Jessica Str{\"o}mberg and Erika Timby and Frank van Broekhoven and Guido A. van Wingen},
  journal={Progress in Neurobiology},
  year={2014},
  volume={113},
  pages={88-94},
  url={https://api.semanticscholar.org/CorpusID:207407084}
}
View on Elsevier
doi.org
183 Citations
Highly Influential Citations
5
Background Citations
54
Methods Citations
4
Results Citations
4

Figures from this paper

183 Citations

GABAA Receptor-Modulating Steroids in Relation to Women’s Behavioral Health

In certain women, increased negative mood relates to the progesterone metabolite, allopregnanolone (allo), during the luteal phase of ovulatory menstrual cycles, the premenstrual dysphoric disorder (PMDD), and this effect can be induced by all GABAA receptor modulators in low concentrations whereas higher concentrations are calming.

Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder

The underlying studies of this review provide evidence that allopregnanolone is the provoking factor behind the negative mood symptoms in PMDD and that isoallopreg nanolone could ameliorate the symptoms as a result of its ability to antagonise the allopreginolone effect on the GABAA receptor.

Progesterone and Its Metabolites Play a Beneficial Role in Affect Regulation in the Female Brain

A new understanding of progesterone-related mood disorders can translate the study results from case series and observational studies to cohort studies, clinical trials, and novel, effective treatment protocols being developed.

GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder

Promising findings from early clinical trials of several compounds that stabilize allopregnanolone signaling during the luteal phase of the menstrual cycle are explored, and GABAergic interventions in PMDD can be used to better understand the relationship between mood states, network regulation, and the balance between excitatory and inhibitory signaling in the brain.

Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone

Prospective studies evaluating associations between psychiatric symptoms and NAS are needed to elucidate the biological causes of the increased rates of psychiatric symptoms among women with PCOS and inform clinical treatment, and allopregnanolone, with its role in normal reproductive function, menstrual dysregulation, makes it a particularly intriguing candidate for future investigation.

Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder

Altered alterations in APS suggest potential GABA-A-R changes across the menstrual cycle and in response to sertraline among treatment responders, suggesting impaired ability to modulate arousal reactivity.

Allopregnanolone and reproductive psychiatry: an overview

An overview of the relationship between allopregnanolone and mood at menarche, in the menstrual cycle; in the peripartum; and in the menopausal transition finds ALLO dysregulation is identified in all of these transitions and found to be associated with mood symptoms.

Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice

An update of the literature on the possible appearance of depressive symptoms when using hormonal contraceptives is provided, and the possible explanations of this problem are investigated based on animal and human studies.

The Allopregnanolone Response to Acute Stress in Females: Preclinical and Clinical Studies

The blunted allopregnanolone response to acute stress, often observed in female rats and women, may represent one of the mechanisms that contribute to the increased vulnerability to stress and affective disorders in women under the different hormonal fluctuations that occur throughout their lifespan.

Progesterone, reproduction, and psychiatric illness.

...

85 References

The Role of Hormones and Hormonal Treatments in Premenstrual Syndrome

SSRIs and substances inhibiting ovulation, such as gonadotrophin-releasing hormone (GnRH) agonists, have proven to be effective treatments and add-back hormone replacement therapy is recommended to avoid adverse effects when high dosages of GnRH agonists are sed.

Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: A pilot study

Progesterone selectively increases amygdala reactivity in women

Investigating whether a single progesterone administration to healthy young women in their follicular phase modulates the amygdala response to salient, biologically relevant stimuli reveals a neural mechanism by which progester one may mediate adverse effects on anxiety and mood.

Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome

Treatment response, whether induced by buserelin or placebo, appears to be associated with a decrease in allopregnanolone concentration, which was associated with improvement in symptoms compared with pre-treatment ratings.

Pharmacokinetic and behavioral effects of allopregnanolone in healthy women

The behavioral effects of allopregnanolone are similar to that of its 5β-stereoisomer, pregnanolone, and decreases saccadic eye movement parameters and increases subjective ratings of sedation that correlate with increased serum concentrations of this neuroactive steroid.

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.

GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid

In this model, withdrawal of progesterone leads to increased seizure susceptibility and insensitivity to benzodiazepine sedatives through an effect on gene transcription, which is due to reduced levels of 3α,5α-THP which enhance transcription of the α4 subunit of the GABAA receptor.

Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.

It is demonstrated that although men show an age-related decrease, serum allopregnanolone levels in women do not change with age and correlate with P levels during the menstrual cycle and in response to endocrine tests.

Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone

Patients with Premenstrual Syndrome Have a Different Sensitivity to a Neuroactive Steroid during the Menstrual Cycle Compared to Control Subjects

Control subjects increased their SEV response to pregnanolone in the luteal phase compared to the follicular phase, whereas PMS patients did not, compatible with a decreased GABAA-receptor sensitivity in brain areas controlling saccadic eye movements among PMs patients in the late luteAL phase.
...